Extended indication Treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis with liver fibrosis
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Semaglutide
Domain Metabolism and Endocrinology
Reason of inclusion Indication extension IND
Main indication Liver diseases
Extended indication Treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis with liver fibrosis
Manufacturer Novo Nordisk
Mechanism of action GLP-1 receptor agonist
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date March 2025
Expected Registration October 2025
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

References NCT04822181 (ESSENCE)

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Cost 1,400.00 - 2,900.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

References Medicijnkosten.nl
Additional remarks 13 pennen semaglutide (4 toedieningen van 0,5 mg) kosten in totaal €1.433,53. 26 pennen semaglutide (2 toedieningen van 1,0 mg) kosten in totaal €2.867,07

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information